Search results
Showing 136 to 150 of 721 results for must
This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.
View quality statements for QS24Show all sections
Sections for QS24
- Quality statements
- Quality statement 1: Screening for the risk of malnutrition
- Quality statement 2: Treatment
- Quality statement 3: Documentation and communication of results and nutrition support goals
- Quality statement 4: Self-management of artificial nutrition support
- Quality statement 5: Review
- About this quality standard
This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.
Acutely ill adults in hospital: recognising and responding to deterioration (CG50)
This guideline covers how patients in hospital should be monitored to identify those whose health may become worse suddenly and the care they should receive. It aims to reduce the risk of patients needing to stay longer in hospital, not recovering fully or dying. It doesn’t specifically cover the care of children, patients in critical care areas or those in the final stages of a terminal illness.
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.
This quality standard covers assessing, diagnosing and managing bronchiolitis in children. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on percutaneous vertebroplasty for spinal metastases. This involves injecting a special bone cement into the spine to relieve pain and stabilise the fracture site.
View recommendations for HTG3Show all sections
Sections for HTG3
Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb (HTG339)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb. This involves dividing appropriate parts of the sympathetic chain beside the vertebral column to reduce sweating.
Unintentional injuries on the road: interventions for under 15s (PH31)
This guideline covers road speed limits, 20 mph zones and engineering measures to reduce speed or make routes safer.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.
International collaboration with NICE